PharmAust presented at the Techknow Invest Roadshow! 🚀🎤 Check out our presentation on advancing ALS/MND treatments with monepantel. Watch here: youtube.com/watch?v=2zh9wJ…

PharmAust (ASX: PAA) is featured in Stockhead's Health & Biotech Investor Guide FY2025! 🌟 Proud to be recognized among top healthcare innovators. Dive into the guide to learn more about our journey and future prospects. 📈🔬 #PharmAust #Biotech #ALS #Healthcare #ASX

PharmAust announces positive interim results from the Open-Label Extension study in ALS! 4 months of monepantel treatment shows promising survival benefits and slowed disease progression. We're committed to advancing this crucial research. #ALS #biotech #innovation

PharmAust has released promising interim results from its ongoing open-label extension study of its lead drug monepantel to treat Amyotrophic Lateral Sclerosis. buff.ly/3AIZAcA @PharmAust #ASX $PAA

🚀 Excited to launch our new podcast, "Neural Threads"! 🧬 Hosted by CSO Nicky Wallis, dive into the latest in biotech with a focus on neurodegenerative diseases & innovative therapies. youtube.com/watch?v=u-oLwD…

PharmAust’s breakthrough drug monepantel is generating buzz with its promising results in treating MND/ALS, potentially transforming the future for patients and offering investors a lucrative opportunity. buff.ly/4cIwPtO @PharmAust #ASX $PAA

Excited to see Dr. Susan Mathers present the promising Phase 1 results of monepantel in ALS patients at the MND Research Symposium in Melbourne. A crucial step forward in improving lives worldwide! 🌍🔬 #ALS #MND #Research #Pharmaust

Exciting to see The Australian feature Pharmaust in an article about our recent Morgans coverage! 🚀 The potential upside for monepantel is gaining recognition. Check out the full story in The Australian: theaustralian.com.au/business/stock… #Pharmaust #Biotech #ALS #TheAustralian

📢 PharmAust is thrilled to share an exclusive interview with Dr. Michael Thurn ahead of our participation at the Spark+ Australian Equities Day in Singapore on Sept 20! 🔗 Watch the full interview & register: linkedin.com/feed/update/ur…

📎PharmAust submits Orphan Medicinal Product Designation request to EMA for monepantel, targeting ALS! If granted, this would provide regulatory support & 10 years of EU market exclusivity. Decision expected in Dec 2024. Exciting times ahead! 🌍 #PharmAust #Biotech #ALS

PharmAust has submitted a request for orphan medicinal product designation to the European Medicines Agency for its lead drug monepantel for the treatment of amyotrophic lateral sclerosis (ALS). buff.ly/4gqOXLN @PharmAust #ASX $PAA

💰 PharmAust (ASX: PAA) secures an $887K rebate under Australia’s R&D Tax Incentive, boosting resources for our ALS research and monepantel development! Further rebate expected soon to support our Phase 2/3 trials. #Biotech #ALSResearch #PharmAust

$NUZ $NUZ.ax Neurizon Neurizon Therapeutics Completes Name Change From Pharmaust #asxnews #Pharamaust juststocks.com.au/neurizon-thera…

Stockhead’s Sarah Hughan sits down with Neurizon Therapeutics' chair, Sergio Duchini, to discuss the reasoning behind the company's name change from PharmAust. buff.ly/3Adumdx Neurizon #ASX

🌟 Exciting news from #Neurizon! We've just presented our Phase 1 MEND study data at the 2024 #NEALS Meeting. Key findings: safety, tolerability, and significant survival benefits in #ALS patients with NUZ-001. #Biotech #ALSResearch #Innovation

We are pleased to share Neurizon Therapeutics’ Quarterly Activity Results, highlighting our continued progress in advancing treatments for ALS and other neurodegenerative diseases. Visit our Investor Hub to read the full announcement at: lnkd.in/e6gnnQjH

Neurizon Therapeutics is partnering with GenieUs Genomics to leverage advanced genomic profiling in our Phase 1 MEND study of NUZ-001, to better understand how patients respond to our ALS drug candidate Read the full press release from GeniUs Genomics at: einpresswire.com/article/757429…

European Medicines Agency (EMA) has issued a positive opinion on Orphan Medicinal Product Designation (OMPD) for our lead ALS drug candidate, NUZ-001. Read the full announcement here: investorhub.neurizon.com/announcements/…

Neurizon has entered into a global license agreement with Elanco Animal Health — a strategic step that strengthens our regulatory and manufacturing foundation for NUZ-001 and accelerates our path toward global commercialisation. investorhub.neurizon.com/announcements/…